Wegovy 0.5mg: the second step in your dose schedule

Step 1: why 0.25mg comes first, and what changes when you move to 0.5mg

Wegovy's schedule is designed in monthly steps. The first pen (0.25mg weekly) has one job: letting your body adjust to semaglutide before the dose climbs. Nausea and digestive discomfort tend to be at their sharpest when treatment starts or a new level is introduced, so beginning at the lowest possible level reduces that disruption significantly.

When you move to 0.5mg at week five, most people notice the appetite-suppressing effect becoming more noticeable. Semaglutide works as a GLP-1 receptor agonist, mimicking a gut hormone that signals fullness and slows how quickly your stomach empties. At 0.5mg that signal is meaningfully stronger than at 0.25mg. The full Wegovy dose range runs from 0.25mg through to 2.4mg (and, following MHRA approval in early 2026, up to 7.2mg for eligible patients) so 0.5mg sits early in that progression.

A practical habit worth building now: check the pen's expiry date and storage condition each time you open the fridge. Wegovy pens should be kept refrigerated between 2°C and 8°C; if yours has been left out, the Patient Information Leaflet sets out the exact room-temperature window you're allowed. One quick look before each weekly injection takes under a minute and avoids a wasted pen.

The NHS semaglutide medicines page covers the dose schedule and what to do if you miss an injection, essential reading alongside your prescriber's instructions.

Step 2: side effects that are most common at this stage of treatment

The gastrointestinal effects of Wegovy are well documented and tend to peak when a new dose level is introduced. At 0.5mg, the effects most commonly reported include nausea, loose stools or constipation, burping, and a feeling of fullness that arrives faster than usual during meals. For most people these settle within one to two weeks at the new level.

Practical measures that many patients find helpful (eating more slowly, opting for smaller portions, and staying well hydrated) are worth discussing with your prescriber or a dietitian. These are not guaranteed to eliminate side effects, but the clinical evidence from the STEP programme suggests the majority of participants tolerated the titration schedule with manageable side effects when they followed guidance on diet and hydration.

There are symptoms that require prompt medical attention regardless of your dose: severe stomach pain that radiates toward your back, with or without vomiting, can be a sign of pancreatitis and should not be waited out. The MHRA highlighted this risk in a January 2026 Drug Safety Update on GLP-1 medicines. If you notice any allergic reaction, such as swelling, rash, or difficulty breathing, seek emergency care immediately. You can also report any suspected side effects directly via the MHRA Yellow Card scheme.

Side effects experienced at 0.5mg do not reliably predict how you will respond to higher doses; each step is its own adjustment period. Your prescriber will want to know how you are getting on before the next increase is confirmed, that clinical check matters.

Step 3: what comes after 0.5mg, and how the schedule progresses

After four weeks at 0.5mg, the standard pathway moves to 1.0mg. To read more about that transition, the 1.0mg Wegovy page covers what changes at that level and what the clinical evidence says about results at the mid-range doses.

The schedule continues through 1.7mg and on to the 2.4mg maintenance dose, which was the standard endpoint in the STEP 1 trial. That trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg dose. Since then the MHRA has approved a higher 7.2mg dose (initially delivered as three 2.4mg pens weekly, and from April 2026 as a dedicated single-dose pen) for adults with a BMI of 30 or above.

Whether you will reach any particular dose, and how quickly, depends on your clinical picture. Some people stay at an intermediate step if they are responding well or tolerating it better at that level. That decision belongs with your prescriber, not with the schedule on paper.

For a broader look at how Wegovy fits into the UK weight management landscape (including NHS access criteria and what private treatment involves) the weight loss overview is a useful starting point. You can also explore what the 2.5mg step involves if you are further along the titration pathway and want to understand what to expect, or review the 5mg Wegovy information if your dose journey is progressing toward that level.

If you have questions about your current dose, the pace of titration, or whether Wegovy is right for you, the right next step is a clinical conversation. You can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.